Download presentation
Presentation is loading. Please wait.
Published byHarriet Cathleen Gilmore Modified over 8 years ago
1
Central Nervous System Stimulants and Attention-Deficit/Hyperactivity Disorder
2
CNS Stimulants Increase the activity of CNS neurons Enhance neuronal excitation; a few suppress neuronal inhibition In sufficient doses, all can cause convulsions Limited clinical applications
3
CNS Stimulants and Attention- Deficit/Hyperactivity Disorder Amphetamines Methylphenidate and dexmethylphenidate Methylxanthines Miscellaneous stimulants Attention-deficit/hyperactivity disorder (ADHD)
4
Amphetamines Chemistry Dextroamphetamine and levamphetamine Amphetamine Lisdexamfetamine Methamphetamine Mechanism of action Release norepinephrine (NE) Release dopamine (DA)
5
Amphetamines Pharmacologic effects Central nervous system Cardiovascular system Tolerance With regular use, develops to elevation of mood, suppression of appetite, and stimulation of the heart and blood vessels Physical dependence Abstinence syndrome with abrupt withdrawal Abuse High potential for abuse due to euphoria
6
Fig. 36 – 1. Structural formulas of the amphetamines.
7
Amphetamines Adverse effects CNS stimulation Weight loss Cardiovascular effects Psychosis
8
Amphetamines Toxicity Dysrhythmias Hypertension Dizziness Confusion Hallucinations Convulsions Paranoid delusions Coma Palpitations Cerebral hemorrhage
9
Amphetamines Treatment Chlorpromazine: hallucinations Alpha-adrenergic blocker: hypertension Diazepam: seizures Therapeutic uses ADHD Narcolepsy
10
Amphetamines Preparations, dosage, and administration Dextroamphetamine sulfate Short duration (Dexedrine, Dextrostat) Long duration (Dexedrine Spansules) Amphetamine/dextroamphetamine mixture Short duration (Adderall) Long duration (Adderall-XR) Methamphetamine (Desoxyn)
11
Methylphenidate and Dexmethylphenidate Methylphenidate and dexmethylphenidate are nearly identical in structure and pharmacologic actions The pharmacology of both drugs is nearly identical to that of amphetamines
12
Methylphenidate ADHD and narcolepsy Trade names Ritalin, Metadate, Methylin, Concerta, Daytrana 50:50 mixture of dextro and levo isomers Preparations, dosage, and administration Short duration Ritalin, Methylin Ritalin, Methylin Intermediate duration Ritalin SR, Metadate ER, Methylin ER Ritalin SR, Metadate ER, Methylin ER Long duration Concerta, Metadate CD, Ritalin LA Concerta, Metadate CD, Ritalin LA
13
Dexmethylphenidate (Focalin) Drug for ADHD Dextro isomer of methylphenidate 50:50 mixture of dextro and levo isomers Schedule II drug
14
Methylxanthines Derivatives of xanthine Caffeine Few clinical applications Few clinical applications Widespread ingestion for nonmedical purposes Widespread ingestion for nonmedical purposes Dietary sources Chocolate Chocolate Desserts Desserts Soft drinks Soft drinks Cola nut Cola nut
15
Methylxanthines Mechanism of action Reversible blockade of adenosine receptors Calcium permeability Accumulation of cyclic AMP Low doses Decrease drowsiness and fatigue and increase capacity for prolonged intellectual exertion Increasing doses Nervousness, insomnia, tremors Seizures with very large amounts AMP = adenosine monophosphate.
16
Fig. 36 – 2. Structural formulas of the methylxanthines.
17
Methylxanthines Pharmacologic effects Central nervous system Heart Blood vessels Bronchi Kidney Reproduction Pharmacokinetics Readily absorbed from the GI tract Achieve peak plasma levels within 1 hour Eliminated by hepatic metabolism
18
Methylxanthines Therapeutic uses Neonatal apnea Promoting wakefulness Other applications Acute toxicity Stimulation of the CNS Tachycardia Respiratory stimulation Sensory phenomena
19
Methylxanthines Preparations, dosage, and administration For promoting wakefulness For neonatal apnea Theophylline Theobromine
20
Miscellaneous CNS Stimulants Pemoline Actions, uses, and adverse effects Causes less cardiac stimulation and vasoconstriction Causes less cardiac stimulation and vasoconstriction Can cause liver failure Can cause liver failure Preparations, dosage, and administration
21
Miscellaneous CNS Stimulants Modafinil (Provigil, Alertec) Therapeutic use Promotes wakefulness Promotes wakefulness Mechanism of action Pharmacokinetics Rapidly absorbed in the GI tract Rapidly absorbed in the GI tract Elimination by hepatic metabolism Elimination by hepatic metabolism Half-life: about 15 hours Half-life: about 15 hours
22
Miscellaneous CNS Stimulants Modafinil (Provigil, Alertec) (cont’d) Adverse effects Headache Headache Nausea Nausea Nervousness Nervousness Diarrhea Diarrhea Rhinitis Rhinitis Drug interactions Oral contraceptives Oral contraceptives Cyclosporine Cyclosporine
23
Miscellaneous CNS Stimulants Modafinil (Provigil, Alertec) (cont’d) Preparations, dosage, and administration Blockade Strychnine: not used as a medicine Poisoning Causes: accidental ingestion, street drugs Causes: accidental ingestion, street drugs Symptoms: convulsions, depression Symptoms: convulsions, depression Treatment: intravenous diazepam, general anesthesia, or neuromuscular blocker Treatment: intravenous diazepam, general anesthesia, or neuromuscular blocker Armodafinil Doxapram Cocaine
24
Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Signs and symptoms Inattention Hyperactivity Impulsivity Fidgety Unable to concentrate
25
ADHD in Children Signs and symptoms (cont’d) Unable to wait his or her turn Switches excessively from one activity to another Calls out excessively in class Present before age 7 years Present for at least 6 months
26
ADHD in Children Etiology Management overview Cognitive therapy Stimulant drugs Drug therapy I: CNS stimulants Methylphenidate (Ritalin, Concerta, others) Dexmethylphenidate (Focalin) Dextroamphetamine (Dexedrine, others) Amphetamine mixture (Adderall) Pemoline (Cylert)
27
ADHD in Children Drug therapy II: atomoxetine Description and therapeutic effects Nonstimulant Nonstimulant No potential for abuse No potential for abuse Administered once a day Administered once a day
28
ADHD in Children Drug therapy II: atomoxetine (cont’d) Mechanism of action Selective inhibitor of NE reuptake Selective inhibitor of NE reuptake Pharmacokinetics Plasma levels peak in 1–3 hours Plasma levels peak in 1–3 hours Metabolized in the liver Metabolized in the liver
29
ADHD in Children Drug therapy II: atomoxetine (cont’d) Adverse effects GI reactions GI reactions Reduced appetite Reduced appetite Dizziness Dizziness Somnolence Somnolence Mood swings Mood swings Trouble sleeping Trouble sleeping
30
ADHD in Children Drug therapy II: atomoxetine (cont’d) Drug interactions MAO inhibitors (isocarboxazid, phenelzine) MAO inhibitors (isocarboxazid, phenelzine) CYP2D6 (paroxetine, fluoxetine, quinidine) CYP2D6 (paroxetine, fluoxetine, quinidine) Role in ADHD therapy Preparations, dosage, and administration Children who weigh less than 70 kg Children who weigh less than 70 kg Children who weigh 70 kg or more Children who weigh 70 kg or more
31
ADHD in Children Drug therapy III: antidepressants Tricyclic antidepressants Decrease hyperactivity Decrease hyperactivity Little effect on impulsivity and inattention Little effect on impulsivity and inattention Second-line drugs Second-line drugs Bupropion (Wellbutrin) Can reduce behavioral symptoms Can reduce behavioral symptoms Less effective than stimulants Less effective than stimulants Poses risk of seizure Poses risk of seizure Second-line drug Second-line drug
32
ADHD in Adults Drug therapy III: antidepressants 60% of ADHD cases persist into adulthood Symptoms Poor concentration Poor concentration Stress intolerance Stress intolerance Antisocial behavior Antisocial behavior Outbursts of anger Outbursts of anger Inability to maintain a routine Inability to maintain a routine Drug therapy Methylphenidate Methylphenidate
33
Drugs Used for ADHD Drug therapy Methylphenidate (Ritalin, Concerta) Dexmethylphenidate (Focalin) Dextroamphetamine (DextroStat) Amphetamine mixture (Adderall) Nonstimulants Atomoxetine (Strattera) Guanfacine (Intuniv) Clonidine (Kapvay)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.